Acrivon Therapeutics, Inc. 8-K

What Happened Acrivon Therapeutics, Inc. filed an 8-K on June 17, 2026 reporting results from its 2026 Annual Meeting of stockholders. Stockholders elected Michael Tomsicek, M.B.A., and Charles Baum, M.D., Ph.D., as Class I directors (terms to the 2029 annual meeting), ratified PricewaterhouseCoopers LLP as independent auditor for fiscal 2026, and approved the Amended and Restated 2022 Equity Incentive Plan.

Key Details

• Quorum: 31,336,993.43 shares present or represented (73.21% of outstanding shares as of the April 23, 2026 record date).
• Directors elected:
  • Michael Tomsicek — For: 24,020,408; Withheld: 1,229,385; Broker non-votes: 6,087,200.
  • Charles Baum — For: 23,657,074; Withheld: 1,592,719; Broker non-votes: 6,087,200.
• Auditor ratified: PwC ratified by vote of 31,278,962 For; 53,857 Against; 4,174 Abstain.
• Equity plan approved: The Amended and Restated 2022 Equity Incentive Plan increases the share reserve to 8,606,723 shares (includes a 3,000,000 share increase approved at the meeting). The plan also provides for automatic annual increases on January 1 through 2032 equal to 5% of the company’s fully diluted shares (unless the board sets a lesser amount).

Why It Matters

• Governance: Election of two Class I directors solidifies board composition through 2029 and maintains continuity of leadership; ratification of PwC preserves the company’s auditor relationship.
• Equity and dilution: Approval of the amended equity incentive plan expands the pool of shares available for employee, director and consultant awards (currently 8.6M shares plus future automatic increases), which can dilute existing shareholders over time as awards vest or are exercised.
  Investors should note these governance and equity-issuance changes when assessing ownership dilution and board oversight; the full plan text is filed as Exhibit 10.1 to the 8-K.